New Medicines Decisions for February 2025

Pomalidomide in combination with dexamethasone				
SMC Drug ID	**Conditions**	**Decision**	**Date published on SMC Website**	**Date of decision / Expected date of decision**
NCMAG119	For treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide, and where more effective alternatives are not suitable. Off-label use.	Available in line with local or regional guidance	27/02/2025	26/03/2025
Other Decision Specified : National Cancer Medicines Advisory Group (NCMAG) Programme				
Web Link : https://www.healthcareimprovementscotland.scot/wp-content/uploads/2025/02/NCMAG119-Pom-Dex-Advice-Document-v1.0.pdf				

Pomalidomide in combination with bortezomib plus dexamethasone				
SMC Drug ID	**Conditions**	**Decision**	**Date published on SMC Website**	**Date of decision / Expected date of decision**
NCMAG120	For treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide. On-label use and off-patent medicine.	Available in line with local or regional guidance	27/02/2025	23/04/2025
Other Decision Specified : National Cancer Medicines Advisory Group (NCMAG) Programme				
Web Link : https://www.healthcareimprovementscotland.scot/wp-content/uploads/2025/02/NCMAG120-Pom-Dex-Bort-Advice-Document-v1.0.pdf				

New Medicines Decisions for February 2025

lecanemab (Leqembi®)				
SMC Drug ID	**Conditions**	**Decision**	**Date published on SMC Website**	**Date of decision / Expected date of decision**
SMC2700	for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients that are apolipoprotein E ε 4 (ApoEε4) heterozygotes or non-carriers.	Not routinely available as not recommended for use in NHS Scotland	10/02/2025	22/01/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/8949/lecanemab-leqembi-final-jan-2025-amended-030225-070225-for-website.pdf				

New Medicines Decisions for February 2025

cabotegravir prolonged-release suspension for injection and film-coated tablets (Apretude®)				
SMC Drug ID	**Conditions**	**Decision**	**Date published on SMC Website**	**Date of decision / Expected date of decision**
SMC2718	Cabotegravir prolonged-release injection: in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents, weighing at least 35 kg. Cabotegravir tablets: in combination with safer sex practices for short term pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents, weighing at least 35 kg. Cabotegravir tablets may be used as: oral lead-in to assess tolerability of cabotegravir prior to administration of long acting cabotegravir injection. oral PrEP for individuals who will miss planned dosing with cabotegravir injection. SMC restriction: Adults and adolescents (weighing at least 35kg) at high risk of sexually acquired HIV who are eligible for PrEP, including oral PrEP, but for whom oral PrEP is not appropriate to meet their HIV prevention needs.	Not routinely available as there is a local preference for alternative medicines	10/02/2025	04/04/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/8943/cabotegravir-apretude-final-jan-2025-for-website.pdf				

New Medicines Decisions for February 2025

cemiplimab (Libtayo®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2719	As monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.	Available in line with local or regional guidance	10/02/2025	04/04/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/8944/cemiplimab-libtayo-final-jan-2025-for-website.pdf				

netarsudil plus latanoprost (Roclanda®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2720	for the reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction. SMC restriction: for use in patients for whom treatment with a prostaglandin analogue alone provides insufficient IOP reduction, only if: the patient has then tried a fixed-dose combination treatment and it has not sufficiently reduced IOP, or a fixed-dose combination treatment containing beta-blockers is unsuitable	Not routinely available as there is a local preference for alternative medicines	10/02/2025	04/04/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/8941/netarsudil-latanoprost-roclanda-final-jan-2025-for-website.pdf				

New Medicines Decisions for February 2025

fenfluramine (Fintepla®)				
SMC Drug ID	**Conditions**	**Decision**	**Date published on SMC Website**	**Date of decision / Expected date of decision**
SMC2723	treatment of seizures associated with Lennox-Gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older. SMC restriction: patients whose seizures have not been controlled after trying two or more anti-epileptic medicines.	Available in line with national guidance	10/02/2025	17/09/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/8948/fenfluramine-fintepla-final-jan-2025-amended-070225-for-website.pdf				

durvalumab (Imfinzi®)				
SMC Drug ID	**Conditions**	**Decision**	**Date published on SMC Website**	**Date of decision / Expected date of decision**
SMC2734	in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).	Available in line with local or regional guidance	10/02/2025	17/09/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/8945/durvalumab-imfinzi-abbreviated-final-jan-2025-for-website.pdf				

New Medicines Decisions for February 2025

olaparib (Lynparza®)				
SMC Drug ID	**Conditions**	**Decision**	**Date published on SMC Website**	**Date of decision / Expected date of decision**
SMC2737	Monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2−negative locally advanced or metastatic breast cancer (mBC). Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with HR+ breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.	Available in line with local or regional guidance	10/02/2025	04/04/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/8942/olaparib-lynparza-final-jan-2025-for-website.pdf				